VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

ALVAC-RHDV (vCP309)
Vaccine Information
  • Vaccine Name: ALVAC-RHDV (vCP309)
  • Target Pathogen: Rabbit hemorrhagic disease virus
  • Target Disease: Rabbit hemorrhagic disease
  • Vaccine Ontology ID: VO_0004738
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector: ALVAC vaccine vector
  • Preparation: An ALVAC (canarypox)-based recombinant virus ALVAC-RHDV (vCP309) expressing a native rabbit hemorrhagic disease virus (RHDV) capsid protein was derived and assessed for its protective efficacy in rabbits (Fischer et al., 1997).
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Rabbit Response

  • Vaccination Protocol: Rabbits were inoculated with varying doses of vCP309 (Fischer et al., 1997).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: Rabbits were challenged with RHDV (Fischer et al., 1997).
  • Efficacy: Protection against a lethal RHDV challenge was demonstrated in rabbits inoculated twice with either high (10(7) p.f.u.) or low (10(5) p.f.u.) doses of vCP309. However, animals in the high dose group developed significantly higher antibody response (Fischer et al., 1997).
References
Fischer et al., 1997: Fischer L, Le Gros FX, Mason PW, Paoletti E. A recombinant canarypox virus protects rabbits against a lethal rabbit hemorrhagic disease virus (RHDV) challenge. Vaccine. 1997; 15(1); 90-96. [PubMed: 9041672].